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Variations in the cost of formal and 
informal health care for patients with 
advanced chronic disease and refractory 
breathlessness: A cross-sectional  
secondary analysis
Mendwas D Dzingina1, Charles C Reilly1, Claudia Bausewein2, 
Caroline J Jolley3, John Moxham3, Paul McCrone4,  
Irene J Higginson1 and Deokhee Yi1
Abstract
Background: Refractory breathlessness in advanced chronic disease leads to high levels of disability, anxiety and social isolation. 
These result in high health-resource use, although this is not quantified.
Aims: To measure the cost of care for patients with advanced disease and refractory breathlessness and to identify factors associated 
with high costs.
Design: A cross-sectional secondary analysis of data from a randomised controlled trial.
Setting/participants: Patients with advanced chronic disease and refractory breathlessness recruited from three National Health 
Service hospitals and via general practitioners in South London.
Results: Of 105 patients recruited, the mean cost of formal care was £3253 (standard deviation £3652) for 3 months. The largest 
contributions to formal-care cost were hospital admissions (>60%), and palliative care contributed <1%. When informal care 
was included, the total cost increased by >250% to £11,507 (standard deviation £9911). Increased patient disability resulting from 
breathlessness was associated with high cost (£629 per unit increase in disability score; p = 0.006). Increased breathlessness on 
exertion and the presence of an informal carer were also significantly associated with high cost. Patients with chronic obstructive 
pulmonary disease tended to have higher healthcare costs than other patients.
Conclusion: Informal carers contribute significantly to the care of patients with advanced disease and refractory breathlessness. 
Disability resulting from breathlessness is an important clinical cost driver. It is important for policy makers to support and acknowledge 
the contributions of informal carers. Further research is required to assess the clinical- and cost-effectiveness of palliative care 
interventions in reducing disability resulting from breathlessness in this patient group.
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What is already known about the topic?
•• Refractory breathlessness in advanced chronic disease leads to high levels of disability, anxiety and social isolation.
•• These result in high health-resource use, although this is not quantified.
•• We also do not know what factors are associated with high cost in these patients.
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What this paper adds?
•• The largest contributions to formal-care cost were hospital admissions (>60%), while palliative care contributed <1%
•• The total cost of care increased by >250% when informal-care costs were included.
•• Increased patient disability resulting from breathlessness was the main clinical factor associated with increased cost.
Implications for practice, theory or policy
•• Our findings highlight the need for health and social care policy makers to support and acknowledge the contributions 
of informal carers.
•• Further research is required to assess the clinical- and cost-effectiveness of palliative care interventions in reducing dis-
ability resulting from breathlessness in patients with advanced disease and refractory breathlessness.
Introduction
Breathlessness is a common and distressing symptom 
affecting many people with advanced chronic disease. It 
causes substantial disability, anxiety and social isolation 
and is difficult to treat.1–4 Globally, over 75 million people 
have breathlessness annually, including over 58 million 
people with severe lung disease,5 more than 5 million peo-
ple with incurable cancer and more than 12 million people 
with heart failure.6,7
The high symptom burden and progressive nature of 
refractory breathlessness in advanced disease suggest that 
patients will require increasing help from professionals 
and family members. As the underlying disease progresses, 
breathlessness increases and is accompanied by panic.8,9 
This is terrifying for patients and their families and often 
results in emergency hospital admissions.9 Despite the 
concerns about the large resource inputs for these patients, 
there is no evidence on the costs of care for them. Thus, it 
is important to establish the costs of caring for people with 
advanced disease and refractory breathlessness. Such 
information is vital to understand the likely ‘burden’ of the 
condition and to provide a baseline to assess the relative 
economic impact of different treatments. It is conceivable 
that costs will arise as a result of direct healthcare input 
and care provided by other agencies, such as social care 
services. Some unpaid care will also frequently be pro-
vided by family members and/or friends (informal care), 
and this has never been quantified.
The aims of this study were to measure the formal and 
informal costs of care for patients with advanced disease 
and refractory breathlessness and to identify patient and 
clinical factors associated with high costs.
Materials and methods
Design
This study is a cross-sectional secondary analysis of data 
from a randomised controlled parallel-group, pragmatic, 
single-blind fast-track trial (ClinicalTrials.gov, number 
NCT01165034).4 The main study, and also this study, had 
ethical approval from the King’s College Hospital Ethics 
Committee (Ref. 10/H0808/17). Participants provided 
their written consent to participate in the main study. The 
data set used for this cross-sectional secondary analysis 
was anonymised and de-identified prior to analysis. This 
procedure was approved by the Ethics Committee.
Setting and sample
Study participants were included according to a standard 
proforma completed by the identifying clinician. Details of 
the trial have been published elsewhere.4 But in summary, 
participants were adult patients (⩾18 years) with advanced 
disease (e.g. cancer, chronic obstructive pulmonary dis-
ease (COPD), chronic heart failure, interstitial lung dis-
ease (ILD) and motor neuron disease) and refractory 
breathlessness on exertion or rest (Medical Research 
Council (MRC) dyspnoea scale score ⩾2), despite opti-
mum treatment of the underlying disease, as deemed by 
the identifying clinician. Participants were recruited from 
three large teaching hospitals and via general practitioners 
(GPs) in South London.
Procedures
In the main study, data were collected at study entry by 
trained interviewers, usually in participants’ homes. The 
data set used for this cross-sectional secondary analysis 
was collected during the main trial. This data set was 
anonymised and de-identified prior to analysis and com-
prises demographic, clinical outcome assessments and use 
of healthcare services including the Chronic Respiratory 
Disease Questionnaire (CRQ);10,11 Numerical Rating Scale 
(NRS), average, at rest and on exertion;12 London Chest 
Activity of Daily Living (LCADL), a questionnaire of the 
level of disability induced by breathlessness;12 EuroQol 
five dimensions questionnaire (EQ-5D) (three levels);12 
Palliative care Outcome Scale (POS), a 10-item measure 
for advanced disease widely validated in cancer and non-
cancer;13 Hospital Anxiety and Depression Scale (HADS);14 
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and the breathlessness version of the Client Services 
Receipt Inventory15 (CSRI) which has been provided in 
Supplementary File S1. Details of other procedures con-
ducted in the main trial have been published elsewhere.4
Clinical outcomes
Study outcomes included breathlessness mastery (using a 
sub-domain of the CRQ); severity of breathlessness on 
exertion in the previous 24 h, disability (LCADL); health-
related quality of life (EQ-5D); palliative needs (POS); 
breathlessness, fatigue and emotional function (other 
domains of the CRQ); anxiety and depression (HADS) and 
lung function (spirometer).
Service use and cost
A broad costing perspective was taken with services 
including those provided by health and social care agen-
cies and also informal carers. However, societal costs were 
not calculated as this analysis did not include lost produc-
tivity. In this analysis, formal care comprised both direct 
health care and social care. Service use was measured at 
study entry using a version of the Client Service Receipt 
Inventory (CSRI).15 Patients gave details of services used 
during the 3 months prior to study entry.
Services included hospital care, primary health care, 
social care, the provision of aids and home adaptations and 
informal care provided by family members and/or friends. 
Length of hospital admission was recorded, while the 
number of contacts and, where relevant, the mean length 
of these contacts were documented for other services. 
Information was provided on the number of hours that 
family/friends spent providing personal care and help in 
and outside the home and in other tasks, per week.
Costs were calculated by combining resource use data 
with unit costs obtained from standard sources such as the 
National Health Service (NHS) reference cost data16 or the 
Unit Costs of Health and Social Care (Personal Social 
Services Research Unit (PSSRU)),17 where applicable. We 
assumed that in the absence of an informal carer, social 
services would need to provide home care, and therefore, 
the unit cost of a home care worker was used as proxy for 
informal care. Missing values for quantities of resource 
use were imputed using multiple imputation by chained 
equations (MICE) via the ‘ice’ command in Stata.18,19
Statistical analysis
We compared formal and informal health-resource use and 
cost across primary diagnosis using descriptive statistics. 
We used scatter and box plots to graphically examine vari-
ations in costs and Spearman’s Rho to assess correlations.
We used generalised linear models (GLM) to determine 
which factors were associated with cost. The dependent 
variable was cost, while clinical and demographic varia-
bles were used as independent variables. Age and EQ-5D 
index were centred to means to enable appropriate inter-
pretation of intercepts. Spearman’s rank correlations of the 
independent variables were used to determine whether any 
variables were highly correlated and therefore not recom-
mended for inclusion in the same regression model. A high 
correlation was defined as a correlation coefficient 
>|0.7|.20 Where two or more independent variables were 
found to be highly correlated, we conducted univariate 
analysis with the dependent variable and selected the inde-
pendent variable with highest adjusted R2. Separate regres-
sion models were fitted for total cost, health service cost 
and informal care cost. We used the modified Park test21 
and the modified Hosmer–Lemeshow test22 to determine 
the appropriate combination of link function and distribu-
tional family. The analysis was performed using STATA 
release 13.23 This study was reported according to the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) Statement for cross-sectional 
studies.
Regression equation
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where ∝i  is the linear predictor formed from explanatory 
variables and coefficients. ε i  follows gamma distribution 
which has an increasing variation with larger mean. 
g i i( ) log( )µ µ= , where g is the link function.
Results
In all, 105 patients were recruited. The mean age was 67 
years, 61 (58%) were men, over half (54%) had COPD, 
20% had cancer, 18% had ILD, 5% had heart failure and 
3% had other diseases. Patients had severe disease: forced 
expiratory volume (FEV1) was 46% predicted, vital 
capacity (VC) 58% predicted, oxygen saturation at rest 
93%, average breathlessness 5.9/10 and on exertion 
8.3/10. Their mean EQ-5D index score was 0.35, and their 
average total Palliative care Outcome Score was 15/40, 
indicating a disabled group with poor quality of life (see 
Table 1).
The results show high levels of outpatient visits, GP 
contacts, inpatient care and accident and emergency 
attendance. More than 75% received care from family and 
friends (Table 2). The mean total cost of care per patient 
was £11,507 (standard deviation (SD) £9911). Informal 
care accounted for over 70% of this.
Over 64% of informal care cost was accounted for by 
the number of hours: on call (45%), providing help inside 
the home (9%) and providing personal care (8%). Over 
60% of direct healthcare cost was accounted for by hospi-
tal admissions (inpatient care 49.3% and critical care 
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11%). Palliative care (home palliative care and hospice) 
accounted for less than 1% of direct healthcare cost, and 
rehabilitation and other therapies accounted for less than 
5% (Table 2). Over 68% of social care cost was spent on 
providing special beds (52%) and wheel chairs (17%).
Overall, there was a high variation in cost with more 
variation in the cost of informal care when compared to 
formal care, across all diagnoses. The variability in 
healthcare cost was largest for COPD patients (range: 
£53–£22,178), whereas cancer patients had the highest 
variability in informal care cost (range: £0–£43,536) 
(Figure 1).
We found no correlation between direct healthcare and 
informal care costs (Figure 2).
The following independent variables were found to be 
highly correlated (Spearman’s Rho >0.78): three variables 
FEV1 percent predicted, VC percent predicted and CRQ 
dyspnoea and also between NRS average, NRS breathless-
ness at rest and NRS on exertion. FEV1 percent predicted 
and NRS on exertion were selected as they each had higher 
adjusted R2 values in univariate analysis with cost.
The results of GLM regression showed that disability 
resulting from breathlessness was significantly associated 
with high total cost (£629 per unit increase in LCADL total 
score; p = 0.006) as well as informal and direct healthcare 
costs (Table 3). The presence of an informal carer was also 
significantly associated with high total and informal-care 
cost. Increased breathlessness on exertion was associated 
with increased healthcare cost; no other clinical variable 
was significantly associated with cost. Patients with COPD 
tended to have higher healthcare costs than patients with 
cancer, ILD or heart failure (Table 3).
Discussion
This is the first study that examines the cost of care in 
patients with advanced disease and refractory breathless-
ness. Over a period of 3 months, hospital admissions 
(inpatient and critical-care stays) had the largest contribu-
tion to direct healthcare cost (>60%), whereas palliative 
care and rehabilitation accounted for less than 1% and 5%, 
respectively. High healthcare cost was associated with 
increasing disability resulting from breathlessness, breath-
lessness on exertion and a diagnosis of COPD. When 
informal care was included, the total cost of care increased 
by >250%. We also found wide variations in cost.
In these 105 patients with advanced disease and 
refractory breathlessness, we found that the cost of formal 
care was £3253 (equivalent to US$4593.70: using 2014 
Organisation for Economic Co-operation and Development 
(OECD) purchasing power parities (PPP) conversion rate) 
over a period of 3 months. This was mainly accounted for 
by inpatient care, critical-care and outpatient clinics. It 
is difficult to compare our estimates with other studies 
(or patients) because no other studies have examined the 
cost of care in patients with advanced disease and refrac-
tory breathlessness. Nevertheless, the cost estimates we 
observed appear to be higher than the costs observed in 
studies in people with COPD. In the 2011 systematic 
review by Bustacchini et al.,24 which explored the 
economic burden of COPD in those aged 60 years or 
older, mean healthcare costs at 3 months ranged from 
£540.98 (US$763.94) in the United States to £2535.69 
(US$3580.75) in Australia (inflated for the purpose of this 
Table 1. Characteristics of the study participants at study 
entry.
N = 105
Age (years) 67 (10)
Sex
 Women 44 (42%)
 Men 61 (58%)
Diagnosis
 Chronic obstructive pulmonary disease 57 (54%)
 Cancer 21 (20%)
 Interstitial lung disease 19 (18%)
 Heart failure 5 (5%)
 Othera 3 (3%)
Has carer or family member
 Yes 75 (71%)
 No 30 (29%)
Living situation
 Living home 97 (92%)
 Living elsewhere 8 (8%)
EQ-5D indexb 0.35 (0.33)
Clinical variables
 Saturated O2 (%)c 93.6 (3.9)
 POS total score (score range = 0–40)d 15.1 (6.5)
 HADS anxiety (score range = 0–21)d 9.2 (2.7)
 HADS depression (score range = 0–21)d 9.9 (3.2)
 NRS breathlessness worst at rest (0–10)d 4.9 (2.6)
 Predicted FEV1 (% predicted)e 46.2 (23.3)
 Predicted VC (% predicted)e 57.9 (25.7)
 NRS breathlessness on exertion (0–10)1 8.3 (1.4)
 NRS breathlessness average 24 h (0–10)1 5.9 (2.0)
SD: standard deviation; NRS: Numerical Rating Scale; FEV1: forced 
expiratory volume; VC: vital capacity; HADS: Hospital Anxiety and De-
pression Scale; POS: Palliative care Outcome Scale; EQ-5D: EuroQol 
five dimensions questionnaire.
Data are absolute numbers or mean (SD) unless otherwise stated.
a Other diagnoses were left lower lobe collapse of unknown aetiology 
associated with severe symptoms; lupus, shrinking lung syndrome and 
rheumatoid arthritis; and severe asthma and gastro-oesophageal reflux 
disease.
b EQ-5D index scores based on the standard UK population-based 
preference weights with the standard scoring algorithm; 0.0 = death 
and 1.0 = perfect health.
c Measured for 13 patients (3 in breathlessness support service group 
and 10 in control group) while on supplemental oxygen (mean (SD) 
SaO2 = 91.8 (5.1)) and the remainder on room air (mean (SD) 93.8 
(3.6)).
dScale interpretation: high score indicates worse.
eScale interpretation: high score indicates better.
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Table 2. Cost of breathlessness for 3 months prior to recruitment into the study.
Contacts (users) Costsa
 N % Mean SD Min Max Mean SD
Health care
 Inpatient care 43 41 10.5b 7.44 0 11,352 1294 2131
 Critical care 6 6 4.2b 3.13 0 11,890 286 1420
 A&E 39 38 1.7 1.14 0 649 67 115
 Outpatient 75 72 2.8 2.47 0 1330 236 271
 Outpatient otherc 33 32 3.4 4.18 0 1781.25 89 234
 Other doctor 4 4 1.5 1.00 0 222 4 26
 Day hospital 7 7 4.4 2.44 0 1120 42 177
 Hospice 1 1 1.0 0.00 0 132 1 13
 District nurse 28 27 12.0 35.41 0 9450 168 959
 GP 84 81 3.2 3.22 0 1039 130 165
 Practice nurse 15 14 2.0 1.51 0 61 3 9
 Physiotherapist 15 14 7.9 7.26 0 396 19 64
 Occupational therapist 8 8 1.6 1.04 0 132 4 16
 Psychologist 11 11 8.7 17.33 0 8160 126 821
 Other therapies 5 5 2.8 1.92 0 150 4 23
 Rehab (pulmonary) 12 12 6.2 4.92 0 1890 78 300
 Rehab (other) 7 7 4.6 3.82 0 895 23 110
 Home palliative care 16 16 3.6 4.70 0 504 15 62
 Dietician 11 11 1.7 0.71 0 68 3 11
 Other servicesd 13 13 15.6 27.40 0 1500 35 167
 Total healthcare cost (A) 53 22,178 2624 3456
Social care
 Social worker 7 7 1.4 0.79 0 222 8 32
 Home help 15 15 24.8 29.44 0 4860 94 504
 Walking aid 43 43 1 N/A 3 8
 Wheelchair 26 25 1 N/A 104 238
 Commode 12 12 1 N/A 3 7
 Special bed 14 13 1 N/A 327 863
 Bathroom/toilet adaptations 45 43 1 N/A 15 73
 Other equipment 51 49 1.7 1.79 0 1000 75 240
 Total social care cost (B) 0 5793 628 1132
Total formal service cost (A + B) 139 22,573 3253 3652
Informal caree
 Hours on call 51 49 149 48.32 0 12,479 5427 6096
 Help outside homef 78 75 6.6 5.55 0 2228 366 415
 Help with medical procedures 32 31 3.5 3.04 0 4200 326 696
 Help inside the homeg 81 78 18 36.46 0 20,798 1027 2438
 Personal careh 36 35 13 25.81 0 30,240 966 3400
 Other help 6 6 33 66.17 0 12,479 141 1226
Total informal care cost (C) 0 43,536 8254 8777
Total costs (A + B + C) 154 45,818 11,507 9911
SD: standard deviation; GP: general practitioner; A&E: accident and emergency.
a2014 GBP.
bNumber of days on admission.
cOutpatient visits are not directly related with breathlessness or main disease.
dServices such as bereavement service, meals, exercise and Red Cross.
eAverage number of hours used by friends or family members.
fFor example, shopping or going to the appointments.
gFor example, cooking or cleaning.
hFor example, bathing or dressing.
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comparison from 2010 US$ to 2014 GBP using standard 
conversion formulae). Inpatient care was the main driver 
of healthcare cost in the Bustacchini et al.24 review.
Our study suggests that the cost of formal care for 
people with advanced disease and refractory breathless-
ness is very high (more expensive than the cost of COPD). 
This perhaps is a reflection of the high cost of care in the 
last year of life; 25% of annual Medicare hospital costs 
are spent on people in the last year of life in the United 
States, while in the United Kingdom, up to 29% of NHS 
hospital expenditures are for people who are in the last 
year of life.25
This is the first study to quantify the informal care cost 
of advanced disease and refractory breathlessness. We 
found that the cost of informal care in our study was high. 
Including informal care increased the total cost per patient 
Figure 1. Box plots showing medians and 25th and 75th percentiles of healthcare versus informal care cost by diagnosis (number 
of observations in brackets).
Figure 2. Relationship between healthcare cost and informal 
care cost.
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by over 250% from £3253 (US$4593.70) to £11,507 
(US$16,249.52). Informal care was mainly accounted for 
by the time spent supervising a patient (hours on call), and 
to a lesser extent, bathing, dressing, cooking and cleaning. 
This highlights the importance of informal care particular 
in advanced disease. It is essential to account for informal 
care cost because in the absence of informal carers, possi-
bly the same amount of care would need to be provided by 
formal carers via health or social care services. For exam-
ple, certain patients (e.g. patients on medical equipment 
like tracheostomies or non-invasive ventilation or at risk of 
falls) will require 24-h supervision. In the United Kingdom, 
if such patients do not have informal carers, then often 
they are cared for in care-homes where they are supervised 
by formal carers, and the health service bears the cost. 
However, it is conceivable that the time spent on supervi-
sion reported in this study for some patients may have 
been more than what would have been required had such 
supervision been provided by formal carers. Nevertheless, 
if the cost of supervising patients was completely excluded 
from our analysis, informal care would still account for 
more than 50% of the total cost of care. Conversely, it is 
possible that informal carers may have underestimated 
how much time they spent supervising. If cost of supervi-
sion was assumed to be at the maximum for all carers 
(£12,479), then informal care cost would account for more 
than 82% of the total cost of care per patient.
High healthcare cost was associated with increasing 
disability resulting from breathlessness and breathlessness 
on exertion. Also, the healthcare cost for COPD was sig-
nificantly more than lung cancer, ILD. Our results are sup-
ported by evidence from several studies on COPD patients 
which suggest that increased disability and poor physical 
performance are both independently associated with 
increased healthcare utilisation, particularly the risk of 
hospital re-admission.26–32 Further research is required to 
Table 3. Factors associated with costs of breathlessness (results from generalised linear model regression).
N = 105 Total cost (£)a Informal care cost (£)a Healthcare cost (£)a
 β CILL CIUL β CILL CIUL β CILL CIUL
EQ-5D index (centred at mean) 5923 −8647 20,493 −6118 −13,171 935 −3070 −6951 811
HADS depression (=1 if high) 578 −8971 10,127 −3741 −14,085 6604 −1417 −3821 988
HADS anxiety (=1 if high) −1910 −12,194 8373 −3788 −11,859 4283 −1823 −3703 56
LCADL total score 629** 180 1079 411* 61 760 635* 85 1186
POS total score −366 −1467 736 −24 −817 769 −82 −232 68
CRQ mastery −5713 −11,833 407 −2569 −5525 388 −226 −963 511
CRQ fatigue −2062 −6785 2661 −2148 −5429 1133 −118 −751 515
Has carer (=1 if yes) 13,650** 6793 20,507 12,345** 8512 16,178 −492 −2427 1442
FEV1 (% predicted) −40 −217 136 22 –91 135 −21 −48 5
NRS breathless on exertion 700 −2296 3696 944 −2029 3917 699* 243 1155
Age (centred at mean) −165 −477 147 −76 −236 85 −36 −87 16
Female (=1 if yes) −2602 −11,376 6172 −1915 −8627 4798 496 −693 1685
Living situation (ref: lives at 
home)
45,980 −42,090 134,049 16,844 −9906 43,595 10,771 −13,911 35,452
Cohabitee (ref.: wife/husband)
 Partner −12,376 −24,846 93 -8340** −14,842 −1837 −587 −3205 2031
 Son/daughter −2271 −14,876 10,334 −2287 −10,334 5760 −223 −2132 1687
 Other −2851 −11,257 5554 1260 −7708 10,227 −689 −2373 994
Diagnosis (ref: COPD)
 Cancer −3098 −8845 2648 −1224 −4848 2401 −1474** −2397 −551
 Interstitial lung disease −5508 −11,221 205 −2480 −8895 3935 −2256* −3862 −650
 Heart failure 37,077 −1984 76,138 41,871 −1352 85,094 −2297** −3452 −1143
 Other 19,145 −3706 41,997 13,659 −3734 31,051 −831 −2731 1069
Constant 1057** 81 13,837 1** 0 4076 217,597** 10,523 4,499,493
Link function Log Log Log  
Family Gamma Gaussian Poisson  
Prob. H.L.b 0.49 0.082 0.397  
EQ-5D: EuroQol five dimensions questionnaire; HADS: Hospital Anxiety and Depression Scale; POS: Palliative care Outcome Scale; FEV1: forced 
expiratory volume; NRS: Numerical Rating Scale; LCADL: London Chest Activity of Daily Living; CRQ: Chronic Respiratory Disease Questionnaire; 
COPD: chronic obstructive pulmonary disease; CILL: lower limit of confidence interval; CIUL: upper limit of confidence interval.
a2014 GBP.
bThe p value for the modified Hosmer–Lemeshow test.
*p < 0.05; **p < 0.005.
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assess the effectiveness and cost-effectiveness of palliative 
care interventions in reducing disability resulting from 
breathlessness in patients with advanced disease and 
refractory breathlessness.
The presence of a career was found to be associated 
with high cost (both total and informal-care costs) as is to 
be expected. Also, we found a high variation in cost with 
more variation in the cost of informal care when compared 
to formal care. We cannot explain this high variation based 
on our data. However, it is conceivable that such variation 
is either due to random variation or, more likely, due to 
specific factors that we have not measured. We believe 
palliative care may reduce some of this variation. Palliative 
care has been shown to decrease rates of emergency 
department attendance33 and length of hospital stay and to 
increase home-death rates, quality of life and possibly sur-
vival in patients with advanced illness.4
Our study has limitations. First, we did not account for 
drugs in our estimates but assumed that these are included 
in the cost of care, and so, we may have underestimated the 
full cost of care. Studies in elderly patients with COPD sug-
gest that pharmaceutical agents may have a moderate to 
high impact on costs.24 Second, we did not obtain resource 
use estimates from medical records but rather relied on 
self-report which may have introduced recall bias. However, 
self-report of service use has been shown to be reliable.15,34 
Third, we had to assume a proxy cost for informal care. In 
the absence of informal carers, it is unlikely that all patients 
would have received help from social services, but the cost 
of a home care worker should nevertheless indicate the 
value of this informal care. Fourth, the regression model 
only included data recorded as part of the study. It is likely 
that other unmeasured patient characteristics could have 
had some impact on cost. Fifth, our study was also limited 
by a small sample size which made it difficult to conduct 
more extensive analyses, particularly for some disease 
groups (such as cardiac failure where we had only five 
patients). Finally, the data in our study were highly skewed 
and there were a number of ‘zero’ resource use data (i.e. 
instances where costs were ‘£0’ because patients did not 
use any resources), which both reduce the power to detect a 
significant difference. It is conceivable that a larger study 
would highlight other cost drivers in this group.
This study provides the first evidence on the costs of 
caring for people with advanced disease and refractory 
breathlessness; it highlights the likely ‘burden’ of the con-
dition and provides a baseline for assessing the relative 
economic impact of different treatments in future studies. 
Further research is required to assess the effectiveness and 
cost-effectiveness of palliative care interventions in reduc-
ing disability resulting from breathlessness in patients with 
advanced disease and refractory breathlessness.
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